Therapeutic vaccine for chronic diseases after the COVID-19 Era
Open Access
- 8 June 2021
- journal article
- review article
- Published by Springer Nature in Hypertension Research
- Vol. 44 (9) , 1047-1053
Abstract
There is currently a respiratory disease outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After rapid development, RNA vaccines and adenoviral vector vaccines were approved within a year, which has demonstrated the strong impact of preventing infectious diseases using gene therapy technology. Furthermore, intensive immunological analysis has been performed to evaluate the efficiency and safety of these vaccines, potentially allowing for rapid progress in vaccine technology. After the coronavirus disease 2019 (COVID-19) era, the novel vaccine technology developed will expand to other vaccines. We have been developing vaccines for chronic diseases, such as hypertension, for >10 years. Regarding the development of vaccines against self-antigens (i.e., angiotensin II), the vaccine should efficiently induce a blocking antibody response against the self-antigen without activating cytotoxic T cells. Therefore, the epitope vaccine approach has been proposed to induce antibody production in response to a combination of a B cell epitope and exogenous T cell epitopes through major histocompatibility complex molecules. When these vaccines are established as therapeutic options for hypertension, their administration regimen, which might be a few times per year, will replace daily medication use. Thus, therapeutic vaccines for hypertension may be a novel option to control the progression of cerebrovascular diseases. Hopefully, the accumulation of immunological findings and vaccine technology advances due to COVID-19 will provide a novel concept for vaccines for chronic diseases.Keywords
This publication has 40 references indexed in Scilit:
- Therapeutic Vaccines against Human and Rat Renin in Spontaneously Hypertensive RatsPLOS ONE, 2013
- Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in MicePLOS ONE, 2013
- Follicular Helper CD4 T Cells (TFH)Annual Review of Immunology, 2011
- A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicityJournal Of Hypertension, 2007
- Model of the whole rat AT1 receptor and the ligand-binding siteJournal of Molecular Modeling, 2006
- Generation of functional ion-channel tools by E3 targetingNature Biotechnology, 2005
- Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjectsClinical Science, 2004
- Evaluation of two carrier protein–angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in manBritish Journal of Clinical Pharmacology, 2003
- Predominant Autoantibody Production by Early Human B Cell PrecursorsScience, 2003
- Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious ratsBritish Journal of Pharmacology, 2000